Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Multivalent Binding and Biomimetic Cell Rolling Improves the Sensitivity and Specificity of Circulating Tumor Cell Capture.

Myung JH, Eblan MJ, Caster JM, Park SJ, Poellmann MJ, Wang K, Tam KA, Miller SM, Shen C, Chen RC, Zhang T, Tepper JE, Chera BS, Wang AZ, Hong S.

Clin Cancer Res. 2018 Jun 1;24(11):2539-2547. doi: 10.1158/1078-0432.CCR-17-3078. Epub 2018 Mar 15.

PMID:
29545463
2.

Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer.

Wang K, Pearlstein KA, Patchett ND, Deal AM, Mavroidis P, Jensen BC, Lipner MB, Zagar TM, Wang Y, Lee CB, Eblan MJ, Rosenman JG, Socinski MA, Stinchcombe TE, Marks LB.

Radiother Oncol. 2017 Nov;125(2):293-300. doi: 10.1016/j.radonc.2017.10.001. Epub 2017 Oct 16.

3.

Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.

Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, Chai S, Herring LE, Zhang L, Zhang T, DeSimone JM, Tepper JE, Vincent BG, Serody JS, Wang AZ.

Nat Nanotechnol. 2017 Sep;12(9):877-882. doi: 10.1038/nnano.2017.113. Epub 2017 Jun 26.

4.

Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.

Wang K, Eblan MJ, Deal AM, Lipner M, Zagar TM, Wang Y, Mavroidis P, Lee CB, Jensen BC, Rosenman JG, Socinski MA, Stinchcombe TE, Marks LB.

J Clin Oncol. 2017 May 1;35(13):1387-1394. doi: 10.1200/JCO.2016.70.0229. Epub 2017 Jan 23.

5.

Toward a better understanding of task demands, workload, and performance during physician-computer interactions.

Mazur LM, Mosaly PR, Moore C, Comitz E, Yu F, Falchook AD, Eblan MJ, Hoyle LM, Tracton G, Chera BS, Marks LB.

J Am Med Inform Assoc. 2016 Nov;23(6):1113-1120. doi: 10.1093/jamia/ocw016. Epub 2016 Mar 28.

PMID:
27026617
6.

Clinical Translation of Nanomedicine.

Min Y, Caster JM, Eblan MJ, Wang AZ.

Chem Rev. 2015 Oct 14;115(19):11147-90. doi: 10.1021/acs.chemrev.5b00116. Epub 2015 Jun 19. Review. No abstract available.

7.

Hypofractionation for breast cancer: lessons learned from our neighbors to the north and across the pond.

Eblan MJ, Vanderwalde NA, Zeman EM, Jones E.

Oncology (Williston Park). 2014 Jun;28(6):536-46. Review.

8.

Improving chemoradiotherapy with nanoparticle therapeutics.

Eblan MJ, Wang AZ.

Transl Cancer Res. 2013 Aug 1;2(4):320-329.

9.

Brachial plexopathy in apical non-small cell lung cancer treated with definitive radiation: dosimetric analysis and clinical implications.

Eblan MJ, Corradetti MN, Lukens JN, Xanthopoulos E, Mitra N, Christodouleas JP, Grover S, Fernandes AT, Langer CJ, Evans TL, Stevenson J, Rengan R, Apisarnthanarax S.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):175-81. doi: 10.1016/j.ijrobp.2012.03.051. Epub 2012 Jun 1.

PMID:
22658442
10.

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

Sidransky E, Nalls MA, Aasly JO, Aharon-Peretz J, Annesi G, Barbosa ER, Bar-Shira A, Berg D, Bras J, Brice A, Chen CM, Clark LN, Condroyer C, De Marco EV, Dürr A, Eblan MJ, Fahn S, Farrer MJ, Fung HC, Gan-Or Z, Gasser T, Gershoni-Baruch R, Giladi N, Griffith A, Gurevich T, Januario C, Kropp P, Lang AE, Lee-Chen GJ, Lesage S, Marder K, Mata IF, Mirelman A, Mitsui J, Mizuta I, Nicoletti G, Oliveira C, Ottman R, Orr-Urtreger A, Pereira LV, Quattrone A, Rogaeva E, Rolfs A, Rosenbaum H, Rozenberg R, Samii A, Samaddar T, Schulte C, Sharma M, Singleton A, Spitz M, Tan EK, Tayebi N, Toda T, Troiano AR, Tsuji S, Wittstock M, Wolfsberg TG, Wu YR, Zabetian CP, Zhao Y, Ziegler SG.

N Engl J Med. 2009 Oct 22;361(17):1651-61. doi: 10.1056/NEJMoa0901281.

11.

Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease.

Goker-Alpan O, Wiggs EA, Eblan MJ, Benko W, Ziegler SG, Sidransky E, Schiffmann R.

J Pediatr. 2008 Jul;153(1):89-94. doi: 10.1016/j.jpeds.2007.12.023. Epub 2008 Feb 14.

PMID:
18571543
12.

Glucocerebrosidase mutations in Chinese subjects from Taiwan with sporadic Parkinson disease.

Ziegler SG, Eblan MJ, Gutti U, Hruska KS, Stubblefield BK, Goker-Alpan O, LaMarca ME, Sidransky E.

Mol Genet Metab. 2007 Jun;91(2):195-200. Epub 2007 Apr 25.

13.

Glucocerebrosidase mutations are an important risk factor for Lewy body disorders.

Goker-Alpan O, Giasson BI, Eblan MJ, Nguyen J, Hurtig HI, Lee VM, Trojanowski JQ, Sidransky E.

Neurology. 2006 Sep 12;67(5):908-10. Epub 2006 Jun 21.

PMID:
16790605
14.

Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism.

Eblan MJ, Scholz S, Stubblefield B, Gutti U, Goker-Alpan O, Hruska KS, Singleton AB, Sidransky E.

Neurosci Lett. 2006 Aug 14;404(1-2):163-5. Epub 2006 Jun 15.

PMID:
16781064
15.

Skin abnormalities as an early predictor of neurologic outcome in Gaucher disease.

Holleran WM, Ziegler SG, Goker-Alpan O, Eblan MJ, Elias PM, Schiffmann R, Sidransky E.

Clin Genet. 2006 Apr;69(4):355-7. No abstract available.

PMID:
16630170
16.

Perinatal lethal Gaucher disease: a distinct phenotype along the neuronopathic continuum.

Eblan MJ, Goker-Alpan O, Sidransky E.

Fetal Pediatr Pathol. 2005 Jul-Oct;24(4-5):205-22. Review.

PMID:
16396828
17.

Glucocerebrosidase mutations are also found in subjects with early-onset parkinsonism from Venezuela.

Eblan MJ, Nguyen J, Ziegler SG, Lwin A, Hanson M, Gallardo M, Weiser R, De Lucca M, Singleton A, Sidransky E.

Mov Disord. 2006 Feb;21(2):282-3. No abstract available.

PMID:
16261622
18.

The glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews.

Eblan MJ, Walker JM, Sidransky E.

N Engl J Med. 2005 Feb 17;352(7):728-31; author reply 728-31. No abstract available.

Supplemental Content

Loading ...
Support Center